Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide

Authors Mark R Gilbert, Terri S Armstrong

Published 15 January 2008 Volume 2007:3(6) Pages 1027—1033

Mark R Gilbert1, Terri S Armstrong2

1Department of Neuro-Oncology, The University of Texas MD, Anderson Cancer Center, Houston, TX, USA; 2Department of Integrated Nursing Care, University of Texas Science Center – School of Nursing, Houston, TX, USA

Abstract: The prognosis for patients with newly diagnosed malignant gliomas remains poor; however there have been some recent advances in treatment that have generated optimism. Medical management usually includes administration of corticosteroids to control peritumoral edema. Anticonvulsants are indicated for patients with established tumor-related seizures; however, the prophylactic use of anticonvulsants remains controversial. Advances in neurosurgical techniques have improved the safety of tumor resection and most patients undergo the maximal safe surgical debulking of tumor. The tissue sample obtained provides conclusive pathologic diagnosis and tumor classification and extensive tumor resection may impact patient outcome. For glioblastoma, external beam radiation had been the conventional first line treatment; however a recent international phase III trial has provided level 1 evidence that a chemoradiation regimen using external beam radiation plus the oral chemotherapy agent temozolomide provides a survival advantage over radiation alone. Correlative studies were also performed that demonstrated better outcomes for patients with tumors demonstrating methylation (inactivation) of the promoter region of methyl guanine methyltransferase (MGMT) gene. Additional studies are in progress building on the clinical trial results using different dosing schedules of temozolomide and combination regimens. Studies are also underway to develop molecular markers, such as expression of MGMT that may help select the patients most likely to benefit from this treatment.
Keywords: glioblastoma, glioma, temozolomide, MGMT, patient management

Download Article [PDF] 

Readers of this article also read:

Passing through the renal clearance barrier: toward ultrasmall sizes with stable ligands for potential clinical applications

Zhang XD, Yang J, Song SS, Long W, Chen J, Shen X, Wang H, Sun YM, Liu PX, Fan S

International Journal of Nanomedicine 2014, 9:2069-2072

Published Date: 25 April 2014

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 5 December 2008

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis

Jessina C McGregor, George P Allen, David T Bearden

Therapeutics and Clinical Risk Management 2008, 4:843-853

Published Date: 10 October 2008

Hypokalemia secondary to capecitabine: a hidden toxicity?

Muhammad Wasif Saif, Mohammad Houman Fekrazad, Leslie Ledbetter, Robert B Diasio

Therapeutics and Clinical Risk Management 2007, 3:177-180

Published Date: 15 March 2007